Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents

Loading...
Loading...
Mylan N.V.
MYL
today announced that the U.S. Patent and Trademark Office (PTO) has instituted inter partes review (IPR) proceedings against two Copaxone® 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd.  The patents relate to methods for the treatment of multiple sclerosis through the administration of at least three 40 mg subcutaneous injections of glatiramer acetate over a period of seven days with at least one day between each injection. Mylan also has filed another petition for inter partes review of a related patent (U.S. Patent No. 8,969,302), which the PTO is expected to act upon shortly. Mylan CEO Heather Bresch commented, "We believe that the patents at question are invalid and are pleased that, in instituting an inter partes review on all claims, the PTO has determined that there is a reasonable likelihood of prevailing on the invalidity assertion. We believe our generic version of Copaxone 40mg/mL represents an exciting first-to-file opportunity for Mylan." In August 2014, the U.S. Food and Drug Administration accepted Mylan's abbreviated new drug application (ANDA) filing for a three times per
See full press release
Posted In: NewsLegalPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...